WO2011136750A1 - Compositions pharmaceutiques induisant un effet synergique - Google Patents

Compositions pharmaceutiques induisant un effet synergique Download PDF

Info

Publication number
WO2011136750A1
WO2011136750A1 PCT/TR2011/000107 TR2011000107W WO2011136750A1 WO 2011136750 A1 WO2011136750 A1 WO 2011136750A1 TR 2011000107 W TR2011000107 W TR 2011000107W WO 2011136750 A1 WO2011136750 A1 WO 2011136750A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
domperidone
dexlansoprazole
range
Prior art date
Application number
PCT/TR2011/000107
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11720903A priority Critical patent/EP2563341A1/fr
Publication of WO2011136750A1 publication Critical patent/WO2011136750A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl

Definitions

  • the present invention relates to a pharmaceutical combination comprising dexlansoprazole and domperidone, and use of said combination in the treatment of acid-related gastrointestinal disturbances, particularly in the treatment of diseases related with gastroesophageal reflux.
  • Gastroesophageal reflux disease is a common problem though it may present various symptoms.
  • Gastroesophageal reflux disease may lead to serious complications such as vomiting, insufficient weight gain, dysphagia, abdominal and substernal ache, esophagitis and respiratory diseases. This disease is seen in approximately 20% of adults and it results in development of barrett, then esophagus cancer in the long term if not treated.
  • the first step in the treatment of the disease is lifestyle changes. However, only patients with mild symptoms can be relieved by these changes. This has created the need to increase the number of the studies in order to provide effective and reliable treatment.
  • Proton pump inhibitors are the most potent agents in the treatment of reflux disease. Proton pump inhibitors have an inhibitory effect on gastric acid secretion in the treatment of gastroesophageal reflux disease.
  • Dexlansoprazole (Formula I), which is a proton pump inhibitor, is R-enantiomer of lansoprazole.
  • Dexlansoprazole has the chemical structure of (i?)-2-[[3-methyl-4-(2,2,2-trifluoroethoxy) -2-pyridinyl]methylsulphinyl)-lH-benzimidazole.
  • Domperidone which is a prokinetic drug disclosed in the patent numbered US 4,066,772, contributes to alleviate gastroesophageal reflux disease by increasing lower esophageal sphincter (LES) pressure, strengthening the peristaltic activity in esophagus and accelerating stomach discharge.
  • Domperidone has the chemical structure of 5-chloro-l- ⁇ l-[3-(2- oxobenzimidazoline-l-yl)propyl) -4- piperidyl ⁇ benzimidazoline-2-one and it is illustrated as in Formula II below:
  • the combination therapy utilizing the active agents dexlansoprazole and domperidone together induces synergistic effect in the treatment of acid-related gastrointestinal disturbances, particularly in the treatment of diseases related to gastroesophageal reflux.
  • the inventors have observed that a far more superior therapeutic benefit than expected is gained in the case that dexlansoprazole and domperidone are used in combination.
  • use of dexlansoprazole and domperidone in combination is more effective than the treatments comprising the use of dexlansoprazole or domperidone alone.
  • dexlansoprazole and domperidone combination is an effective alternative for cases where the treatments comprising the use of these active agents alone remain incapable.
  • this combination developed in scope of the present invention allows use of the active agents at lower doses than the cases that the two active agents are used alone for the same therapeutic response.
  • the side effects are minimized with the help of use of the active agents at lower doses.
  • the pharmaceutical combinations of the present invention comprise oral, enteral, parenteral (hypodermic, intramuscular, intravaneous) dosage forms.
  • the dosage forms according to the present invention are preferably oral dosage forms and they can be in solid dosage forms such as tablet; orally disintegrating tablet; enteric coated tablet; film coated tablet; modified release tablets such as constant release tablet, prolonged release tablet, delayed release tablet; fast soluble tablet; effervescent tablet; micro tablet; pellets; modified release pellets such as constant release pellet, prolonged release pellet, delayed release pellet; effervescent granule, fast soluble powder mixture or dry powder mixture for syrup preparation, dragee, cachet, capsule or in liquid forms such as suspension.
  • solid dosage forms such as tablet; orally disintegrating tablet; enteric coated tablet; film coated tablet; modified release tablets such as constant release tablet, prolonged release tablet, delayed release tablet; fast soluble tablet; effervescent tablet; micro tablet; pellets; modified release pellets such as constant release pellet, prolonged release pellet, delayed release pellet; effervescent granule, fast soluble powder mixture or dry powder mixture for syrup preparation, dragee, cachet, capsule or in liquid forms such as suspension.
  • compositions of the present invention comprise various pharmaceutically acceptable excipients in addition to pharmaceutically effective amounts of dexlansoprazole and domperidone.
  • the amount of dexlansoprazole used in the formulations of the present invention is in the range of 5 mg to 180 mg, preferably in the range of 10 mg to 120 mg, more preferably in the range of 15 mg to 60 mg, and the amount of domperidone is in the range of 0.25 mg to 100 mg, preferably in the range of 1 mg to 60 mg, more preferably in the range of 5 to 15 mg.
  • D(10) particle size of the active agents used in the formulations of the present invention is smaller than 50 micron; D(50) particle size is smaller than 100 micron; D(90) particle size is smaller than 200 micron.
  • the term "D(10) particle size” used in this text refers to the particle size of 10% of active agent particles by volume; the term “D(50) particle size” refers to the particle size of 50% of active agent particles by volume; the term “D(90) particle size” refers to the particle size of 90% of active agent particles by volume.
  • the pharmaceutically acceptable excipients that can be used in the formulations of the present invention can be selected from the group comprising pH adjusters, stabilizing agents, diluents, binders, coating materials developed to provide various release characteristics, disintegrants, anti-adhesive agents, plasticizers, rate controlling agents, filling materials, glidants, coloring agents, aqueous or non-aqueous solvents or combinations thereof.
  • the stabilizing agents that can be used in the formulations of the present invention can be selected from the group comprising basic substances such as calcium carbonate, dibasic calcium phosphate dihydrate, calcium sulphate anhydrous, calcium sulphate dihydrate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium sulphate, potassium bicarbonate, potassium hydroxide, dibasic potassium phosphate, sodium hydroxide, sodium bicarbonate, sodium carbonate, dibasic sodium phosphate, tribasic sodium phosphate, magnesium lactate, magnesium gluconate, aluminum hydroxide, sodium citrate, sodium tartrate, sodium polyphosphate, potassium polyphosphate, sodium acetate, calcium acetate, potassium metaphosphate, calcium glycerophosphate, calcium lactate and calcium bicarbonate or combinations thereof.
  • Total amount of the stabilizing agent in the formulations of the present invention is in the range of 1% to 30% by weight.
  • the diluents that can be used in the formulations of the present invention can be selected from the group comprising calcium carbonate, calcium phosphate-dibasic, calcium phosphate- tribasic, calcium sulphate, microcrystalline cellulose, silicified microcrystalline cellulose, powderized cellulose and derivatives thereof, dextrates, dextrines, dextrose excipients, fructose, kaoline, lactitol, lactose, mannitol, sorbitol, starch and derivatives thereof, sucrose, compressed sugar, powdered sugar or combinations thereof.
  • Total amount of the diluent in the formulations of the present invention is in the range of 10% to 50% by weight.
  • the pH agents that can be used in the formulations of the present invention can be selected from the group comprising magnesium oxide, dibasic calcium phosphate anhydrous, tribasic calcium phosphate, precipitated calcium carbonate, cellulose derivatives comprising powdered cellulose and other substances.
  • the pH agents can optionally be used in combination with the stabilizing agents in scope of the present invention.
  • Total amount of the pH agent in the formulation of the present invention is in the range of 1% to 30% by weight.
  • the binders that can be used in the formulations of the present invention can be selected from the group comprising polyvinylpyrrolidone, hydroxypropyl methylcellulose, acacia, alginate derivatives, hydroxypropyl propyl cellulose, carboxymethylcellulose sodium, compressed sugar, ethyl cellulose, gelatin, liquid glucose, methyl cellulose and pregelatinized starch or combinations thereof.
  • Total amount of the binder in the formulation of the present invention is in the range of 1% to 10% by weight.
  • the filling materials that can be used in the formulations of the present invention can be selected from the group comprising lactose, sugar, starch, modified starch, mannitol, sorbitol, inorganic salts, microcrystalline cellulose, cellulose, calcium sulphate, xylitol, and lactitol or combinations thereof.
  • the enteric coating materials that can be used in the formulations of the present invention can be selected from the group comprising methacrylic copolymers such as methacrylic acid/methyl methacrylate, methacrylic acid/ethyl acrylate copolymers, methacrylic acid/methyl acrylate/ methyl methacrylate copolymers, shellac, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, triethyl citrate, hydroxypropyl methylcellulose trimellitate, cellulose acetate phthalates, polyvinyl acetate phthalates or combinations thereof. It can also comprise other additives along with the polymers counted as enteric coating materials. Talc and titanium dioxide can be given as examples of these additives. Total amount of enteric coating material in the compositions of the present invention is in the range of 1% to 30% by weight.
  • the disintegrants that can be used in the compositions of the present invention can be selected from the group comprising substances such as starch, starch sodium glycolate, croscarmellose sodium, crospovidone, alginate derivatives, carboxymethylcellulose sodium and guar gum or combinations thereof.
  • Total amount of the disintegrant in the compositions of the present invention is in the range of 0.5% to 15% by weight.
  • the lubricants that can be used in the compositions of the present invention can be selected from the group comprising substances such as stearate derivatives such as magnesium stearate, sodium stearil fumarate, calcium stearate, zinc stearate; polyethylene glycol, talc, hydrogenated castor oil, silica, colloidal silica, corn starch, calcium silicate, magnesium silicate and silicon hydrogel or combinations thereof.
  • Total amount of the lubricant in the compositions of the present invention is in the range of 0.1% to 5% by weight.
  • the plasticizers that can be used in the compositions of the present invention can be selected from the group comprising dibutyl sebacate, polyethylene glycol and polypropylene glycol, dibutyl phthalate, diethyl phthalate, triethyl citrate, tributyl citrate, acidified monoglyceride, acetyl tributyl citrate, triacetine, dimethyl phthalate, benzyl benzoate, butyl and/or glycol esters of fatty acids, refined mineral oil, oleic acid, castor oil, maize oil, camphor, glycerol and sorbitol polyethylene glycols, propylene glycol, glycerols, glycerides, fractionated coconut oil and castor oil, citric acid ester, phthalic acid or sebacic acid or combinations thereof. Total amount of the plasticizer in the composition is in the range of 1% to 20% by weight.
  • compositions of the present invention can optionally be formulated such that they can provide various release characteristics, for instance prolonged, delayed, constant release.
  • the rate controlling agents that can be used to determine release characteristics of the formulations can be selected from the group comprising substances such as cellulosic polymers such as ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxy methyl cellulose, hydroxyl methylcellulose and hydroxyethyl cellulose; wax; hydroxypropyl methylcellulose phthalate; cellulose acetate phthalate; cellulose acetate trimellitate; methacrylic acid polymers such as Eudragit RL and RS; polymethacrylates; carboxymethylcellulose sodium; carboxymethyl cellulose calcium; polyacrilic acid; polyethylene glycol; polyethylene oxide; carrageenan; cellulose acetate; zein; carbohydrate gums; polyuronic acid salts; cellulose ethers and acrylic acid polymers or combinations thereof.
  • Total amount of the rate controlling agent in the compositions of the present invention is in the range of 10% to 50% by weight.
  • the aqueous or nonaqueous solvents that can be used in the formulation of the present invention can be selected from the group comprising solvents such as ethanol, methanol, acetone, isopropanol, dichloromethane and water or combinations thereof.
  • the glidants that can be used in the formulation of the present invention can be selected from the group comprising substances such as colloidal silicon dioxide, corn starch, talc, calcium silicate and magnesium silicate or combinations thereof.
  • the coloring agents that can be used in the formulation of the present invention can be selected from the group comprising iron oxide and its derivatives such as red iron oxide, yellow iron oxide; lacquer paint and pharmaceutically acceptable colorants or combinations thereof.
  • compositions to be produced according to the present invention can be prepared such that they comprise the active agents dexlansoprazole and domperidone in separate dosage forms or in a single dosage form, and they can be used simultaneously, sequentially or separately.
  • the active agents are administered separately.
  • the essential factor to obtain good results in pharmacotherapy is patient's compliance with the instructions. Therefore, administration of two or more different dosage forms to the patient does not yield satisfactory results most of the time.
  • the present invention provides new dosage forms formulated in a single dosage form and comprising dexlansoprazole and domperidone together as the active agent. It has been seen that a more effective treatment is provided with the combination of the present invention by formulating dexlansoprazole and domperidone in a single dosage form.
  • an advantage of the invention is that it enhances the adaptation of the patients to the treatment by combining the active agents in a single dosage form.
  • single dosage form refers to formulating the active agents and the excipients together and combining them in a single dosage form as well as formulating the active agents separately as different dosage forms and combining them in a single dosage form.
  • the inventors has unexpectedly observed that there is a positive development in the stability profile of the combined dosage form which was developed in scope of the present invention and obtained by formulating the two active agents separately and combining the unit dosage forms obtained this way in a single dosage form.
  • These dosage forms produced according to the present invention homogenously disperse in gastrointestinal tract and they are transposed to the intestines from the stomach. In this way, it is ensured that the active agents are dispersed effectively in the stomach and therefore, the efficiency and bioavailability of the combined medicament is enhanced.
  • the unit dosage forms according to the present invention can be in physical forms comprising active agent on a pharmaceutically effective amount and excipients such as tablets, micro tablets, coated tablets, effervescent tablets, soluble tablets, pellets, granules, powders, and these unit dosage forms can optionally be coated with protective coating, enteric coating, coloring coating, film coating and/or various coatings aimed to modify release characteristics.
  • the combined dosage forms preferred according to the present invention are obtained by combining independent unit dosage forms selected from the ones listed above that comprise dexlansoprazole and domperidone on pharmaceutically effective amounts preferably in a capsule.
  • the unit dosage forms can optionally be coated with protective coating, enteric coating, film coating, coloring coating and/or different coatings so as to provide various release characteristics.
  • the unit dosage forms of dexlansoprazole according to the present invention can optionally be formulated to be delayed release while the unit dosage forms of domperidone can optionally be formulated to be constant release.
  • the unit dosage forms of present invention comprising domperidone on pharmaceutically acceptable amounts are preferably in granule, powder or pellet form while the unit dosage form comprising dexlansoprazole is preferably in micro tablet form.
  • the unit dosage forms of the present invention are formulated according to the characteristics of the active agent they comprise.
  • pharmaceutically acceptable excipients comprised in separate dosage forms and their amounts can be identical or different.
  • the pellet, granule or powder compositions of domperidone according to the present invention can comprise effective amounts of domperidone and one or more pharmaceutically acceptable excipients described in detail above.
  • the unit dosage forms comprising domperidone can be produced by any method in the prior art.
  • the method preferred to be used in production of powder compositions of domperidone of the present invention is preferably dry mixing wherein said method comprises mixing domperidone on a pharmaceutically effective amount, at least one pharmaceutically acceptable filling material, at least one lubricant and optionally at least another excipient.
  • Domperidone pellets which is another unit dosage form preferred according to the present invention, are preferably constant release pellets and preferably produced by the following method:
  • Domperidone and a pharmaceutically acceptable diluent or some part of the diluent mixture are mixed dry; the coloring agent and the filling material are added into the mixture and they are all mixed again,
  • the dry active agent mixture obtained in the first step is added into the wet diluent granules obtained, they are mixed and pellets are prepared of this mixture,
  • the pellets obtained are coated with the solution prepared by dissolving the rate controlling agent in a suitable solvent.
  • micro tablets of dexlansoprazole preferred according to the present invention are composed of a tablet core comprising dexlansoprazole on an effective amount, at least one pharmaceutically acceptable disintegrants, at least one binder, at least one stabilizing agent, at least one rate controlling agent and optionally at least another excipient; a sub-coat on the core; an enteric coat on the sub-coat and optionally a coloring coat.
  • the stabilizing agents to be used in the micro tablet composition of dexlansoprazole and their amounts are selected such that pH of the composition is at a level to provide minimum degradation of dexlansoprazole.
  • the amount preferred is in the range of 1% to 50%, preferably in the range of 1% to 40%, more preferably in the range of 1% to 30% with respect to weight of the core of the unit dosage form comprising dexlansoprazole.
  • the stabilizing agent used in micro tablets of dexlansoprazole of the present invention can preferably be a magnesium salt, for instance magnesium oxide, magnesium carbonate, magnesium silicate and/or magnesium sulphate.
  • the production method for production of the micro tablets of domperidone of the present invention is preferably wet granulation and it comprises the following steps:
  • a characteristic feature of the production method given above is that the pharmaceutically acceptable excipient in the second step of the method is a stabilizing agent.
  • a characteristic feature of the production method given above is that the mixing time of the lubricant given in the fourth step of the method is in the range of 1 to 20 minutes, preferably in the range of 1 to 10 minutes.
  • the compression force required for compressing micro tablets as given in the fifth step of the method is in the range of 10 to 300 kN, preferably in the range of 10 to 200 kN.
  • micro tablets comprising dexlansoprazole are mixed with unit dosage forms of the present invention comprising domperidone on pharmaceutically effective amounts and they are preferably filled into a capsule made of soft gelatin.
  • unit dosage forms of the present invention comprising domperidone on pharmaceutically effective amounts and they are preferably filled into a capsule made of soft gelatin.
  • Example 1 Film Coated Tablet Composition 25 mg dexlansoprazole and 5 mg domperidone are taken as active agents. The combination of dexlansoprazole and domperidone is granulated with pharmaceutically acceptable excipients. The granules are dried and then sieved under appropriate humidity and temperature conditions. Tablets are compressed from the obtained final product in an appropriate tablet compressing machine. Optionally, tablets can be film coated.
  • Example 2. Combine Dosage Form-I
  • enteric coated micro tablet composition comprising dexlansoprazole so as to be produced according to the formulation given above is as follows:
  • the mixture composed of dexlansoprazole, at least one disintegrant and magnesium oxide agent is granulated by a granulation solution obtained by mixing a pharmaceutically acceptable binder and solvent; the granules are dried and then sieved.
  • the rate controlling agent is added into the garnules obtained and the blend is mixed.
  • the lubricant is added into the mixture and the blend is mixed for 5 minutes.
  • Micro tablets are compressed of the final mixture by imposing 1-300 kN of compression force.
  • micro tablets are coated with subcoating first, then with enteric coating and lastly with coloring coating.
  • the dry active agent mixture is added into the wet diluent granules obtained in the first step; they are mixed and pellets are obtained.
  • IV. The pellets obtained are coated with a solution prepared by dissolving the rate controlling agent in a suitable solvent.
  • Dexlansoprale micro tablets and domperidone pellets produced according to the production methods and the formulation given above are combined preferably in a capsule made of soft gelatin.
  • micro tablet compositions of dexlansoprazole given in examples 3 and 4 are produced according to the production method given in example 2.
  • micro tablets of dexlansoprazole and the powder compositions of domperidone obtained this way are combined in preferably a capsule made of soft gelatin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant du dexlansoprazole et de la dompéridone et l'utilisation de ladite composition dans le traitement de troubles gastro-intestinaux associés à l'acidité, en particulier dans le traitement de maladies associées au reflux gastro-œsophagique.
PCT/TR2011/000107 2010-04-26 2011-04-25 Compositions pharmaceutiques induisant un effet synergique WO2011136750A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11720903A EP2563341A1 (fr) 2010-04-26 2011-04-25 Compositions pharmaceutiques induisant un effet synergique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/03233 2010-04-26
TR201003233 2010-04-26

Publications (1)

Publication Number Publication Date
WO2011136750A1 true WO2011136750A1 (fr) 2011-11-03

Family

ID=44145015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000107 WO2011136750A1 (fr) 2010-04-26 2011-04-25 Compositions pharmaceutiques induisant un effet synergique

Country Status (2)

Country Link
EP (1) EP2563341A1 (fr)
WO (1) WO2011136750A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155430A1 (fr) * 2012-04-13 2013-10-17 Banner Pharmacaps, Inc. Capsules molles élastiques contenant des comprimés et remplies de liquides ou de semi-solides et procédés pour leur fabrication

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
WO1997025065A1 (fr) * 1996-01-08 1997-07-17 Astra Aktiebolag Formes galeniques par voie orale comprenant un inhibiteur de la pompe a protons et un agent pro-cinetique
WO2004071374A2 (fr) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Compositions pharmaceutiques d'administration orale une fois par jour
WO2005023306A2 (fr) * 2003-09-05 2005-03-17 Medley S.A. Indústria Farmacêutica Medicament, trousse de medicaments, combinaison de medicaments, association medicinale et medicament ayant une forme de presentation commode
WO2005065664A1 (fr) * 2004-01-06 2005-07-21 Panacea Biotec Ltd. Compositions pharmaceutiques comprenant un inhibiteur de pompe a protons et un agent pro-cinetique
WO2006011159A2 (fr) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
WO2010038241A2 (fr) * 2008-09-30 2010-04-08 Panacea Biotec Limited Compositions pharmaceutiques comprenant un inhibiteur de pompe à proton, un agent procinétique et un acide alginique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066772A (en) 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
WO1997025065A1 (fr) * 1996-01-08 1997-07-17 Astra Aktiebolag Formes galeniques par voie orale comprenant un inhibiteur de la pompe a protons et un agent pro-cinetique
WO2004071374A2 (fr) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Compositions pharmaceutiques d'administration orale une fois par jour
WO2005023306A2 (fr) * 2003-09-05 2005-03-17 Medley S.A. Indústria Farmacêutica Medicament, trousse de medicaments, combinaison de medicaments, association medicinale et medicament ayant une forme de presentation commode
WO2005065664A1 (fr) * 2004-01-06 2005-07-21 Panacea Biotec Ltd. Compositions pharmaceutiques comprenant un inhibiteur de pompe a protons et un agent pro-cinetique
WO2006011159A2 (fr) * 2004-06-21 2006-02-02 Torrent Pharmaceuticals Limited Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
WO2010038241A2 (fr) * 2008-09-30 2010-04-08 Panacea Biotec Limited Compositions pharmaceutiques comprenant un inhibiteur de pompe à proton, un agent procinétique et un acide alginique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BHAVNA PATEL ET AL: "Simultaneous Estimation of Lansoprazole and Domperidone in Combined Dosage Form by RP-HPLC", ASIAN J. RESEARCH CHEM., vol. 2, no. 2, 1 May 2009 (2009-05-01), pages 210 - 212, XP055000933, Retrieved from the Internet <URL:http://www.ajrconline.org/ajrc_vol2_2/28-101.pdf> [retrieved on 20110617] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155430A1 (fr) * 2012-04-13 2013-10-17 Banner Pharmacaps, Inc. Capsules molles élastiques contenant des comprimés et remplies de liquides ou de semi-solides et procédés pour leur fabrication

Also Published As

Publication number Publication date
EP2563341A1 (fr) 2013-03-06

Similar Documents

Publication Publication Date Title
JP6037840B2 (ja) 口腔内崩壊錠
CA2605839C (fr) Composition stabilisee d&#39;un inhibiteur de pompe a protons
US20080003281A1 (en) Modified Release Tablet Formulations for Proton Pump Inhibitors
JP6364406B2 (ja) 口腔内崩壊錠
MX2007010889A (es) Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina.
JP5925318B2 (ja) 有核錠
WO2006011159A2 (fr) Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
JPWO2008081891A1 (ja) 口腔内崩壊性固形製剤
JPWO2007074910A1 (ja) 放出制御固形製剤
JP2014533656A5 (fr)
JP2015522653A (ja) プロトンポンプ阻害剤の医薬組成物
US11986554B2 (en) Orally disintegrating compositions
WO2017084680A1 (fr) Composition pharmaceutique contenant un médicament anti-inflammatoire non stéroïdien et un inhibiteur de pompe à protons
ZA200606409B (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic
JP2019099567A (ja) 多層構造を有する粒子状医薬組成物
US9040564B2 (en) Stabilized composition
WO2004066982A1 (fr) Compositions orales stables de benzimidazole et leurs procedes de preparation
WO2011136750A1 (fr) Compositions pharmaceutiques induisant un effet synergique
KR102286499B1 (ko) 레날리도마이드를 포함하는 약제학적 조성물
EP4110300A1 (fr) Composition pharmaceutique contenant un composé dérivé de benzimidazole
CN105769824A (zh) 一种兰索拉唑缓释胶囊及其制备方法
TWI606847B (zh) 口腔內崩解錠

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11720903

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011720903

Country of ref document: EP